Monitoring people treated with isotretinoin for depression.
Depression has been reported in some patients treated with isotretinoin, an effective medication for nodulocystic acne, a serious disorder resulting in permanent scarring. Since major depression, a common disorder associated with multiple health risks including suicide attempts and treatment noncompliance, may occur during the course of treatment with isotretinoin, persons treated with isotretinoin must be screened for depression before starting treatment and monitored for depression regularly during the course of treatment with isotretinoin. Those with evidence of depression must then be referred for prompt treatment to abort serious adverse outcomes, including suicide. Psychologists constitute key members of the treatment team of patients taking isotretinoin.
Brasić
James Robert
JR
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287-0807, USA. brasic@jhmi.edu
D003865:Major Depressive Disorder / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D016903:Drug Monitoring; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects*; D007641:Keratolytic Agents / Q000009:adverse effects*; D008403:Mass Screening
D007641:Keratolytic Agents; D015474:Isotretinoin